
9 Meters Biopharma NMTR
Quartalsbericht 2023-Q1
hinzugefügt 15.05.2023
9 Meters Biopharma Betriebsaufwand 2011-2026 | NMTR
Betriebsaufwand Jährlich 9 Meters Biopharma
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 M | 36.8 M | 60.9 M | 24.3 M | 18.2 M | 6.6 M | 6.68 M | 6.89 M | 6.91 M | 3.97 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 60.9 M | 3.97 M | 21.3 M |
Betriebsaufwand Vierteljährlich 9 Meters Biopharma
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.8 M | - | 8.72 M | 11.2 M | 11.4 M | - | 13.5 M | 8.26 M | 5.4 M | - | 6.3 M | 44.8 M | 4.96 M | - | 6.51 M | 6.12 M | 4.31 M | - | -220 K | 3.38 M | 11.3 M | - | 2.34 M | 2.69 M | 3.92 M | - | 2.46 M | 1.33 M | 1.68 M | - | 1.92 M | 1.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 44.8 M | -220 K | 7.34 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Mesoblast Limited
MESO
|
86.7 M | $ 14.32 | 2.14 % | $ 9.29 B | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 215.54 | -1.16 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.23 | - | $ 899 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
85.3 M | $ 8.18 | -2.97 % | $ 109 M | ||
|
MediciNova
MNOV
|
13.7 M | $ 1.45 | - | $ 71.1 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 0.71 | 17.15 % | $ 8.13 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
598 M | $ 41.57 | 0.39 % | $ 11.3 B | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.32 | -5.71 % | $ 337 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Genmab A/S
GMAB
|
67.9 M | $ 25.81 | 0.51 % | $ 16.6 B | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.65 | 0.76 % | $ 16.6 M | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
NovaBay Pharmaceuticals
NBY
|
8.44 M | $ 1.5 | 11.94 % | $ 8.73 M | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.31 | -2.49 % | $ 826 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
752 M | $ 69.68 | -1.57 % | $ 11.1 B | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M |